Research programme: siRNA therapeutics - General Research Laboratory/Sirnaomics

Drug Profile

Research programme: siRNA therapeutics - General Research Laboratory/Sirnaomics

Alternative Names: Anti-fibrosis RNA interference therapeutic - Sirnaomics; Cotsiranib®; STP 503; STP 705; STP 705LU; STP 705LV

Latest Information Update: 09 Nov 2016

Price : $50

At a glance

  • Originator General Research Laboratory; Sirnaomics
  • Developer General Research Laboratory; Sirnaomics; Xiangxue Pharmaceutical
  • Class Small interfering RNA
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors; RNA interference; Transforming growth factor beta1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer; Fibrosis; Hypertrophic scars; Prostate cancer; Wounds

Most Recent Events

  • 07 Nov 2016 US FDA approves IND application for STP 705 in Hypertrophic scars
  • 07 Nov 2016 Sirnaomics plans a phase II trial for Hypertrophic scars in USA
  • 08 Sep 2016 Preclinical trials in Breast cancer in France (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top